D-penicillamine: Its actions on lead transport in bone organ culture

John F. Rosen, Morri E. Markowitz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The purpose of this study was to develop a strictly controlled chemical system in vitro to evaluate the efficacy of lead (Pb) chelators. Moreover, these experiments were carried out to understand further the complex interactions between Pb chelating agents, calcium-regulating hormones, and bone cell metabolism. The effects of D-penicillamine (PC A) on previously incorporated<sup>203</sup>Pb transport from fetal rat bone explants were examined in bone organ culture. In several experiments,<sup>203</sup>Pb and stable bone Pb content were measured, and proportional net losses or gain were found. Experimental medium/control medium (EM/CM) ratios were used to reflect inhibition or stimulation of<sup>203</sup>Pb release because these data were expressed as the net cpm released from treated bones into the EM, defined as a change in one variable, divided by the net cpm released from control bones into the appropriate CM. EM/CM ratios increased significantly (1.96 ± 0.04 to 7.28 ± 0.08) in a dose-response relationship as PCA concentrations were raised from 1.0 to 10.0 mM. Addition of parathyroid hormone (PTH) to the medium resulted in increased EM/CM ratios for<sup>203</sup>Pb at lower PCA concentrations (EM/CM 2.79 ± 0.14 at 0.10 mM PCA; 6.71 ± 0.08 at PCA 5.0 mM), compared to PCA in the media alone. This addition of PTH effected release of 4Scalcium (45Ca) (EM/CM, 1.45 ± 0.07 to 3.62 ± 0.10) at PCA concentrations from 0.10 to 10.0 mM. 1,25- Dihydroxyvitamin D<inf>3</inf> [l,25-(OH)<inf>2</inf>D<inf>3</inf> in combination with PCA enhanced 203Pb release, evidenced by an EM/CM ratio of 5.69 ± 0.14 at 1.0 mM PCA compared to an EM/CM ratio of 1.96 ± 0.04 when only 1.0 mM PCA was present in the medium. A decrease in medium Ca concentration from 1.40 to 0.70 mM in the presence of 1.0 mM PCA and 20 ng/ml 1,25-dihydroxyvitamin D<inf>3</inf> enhanced the net release of 20SPb as well. In contrast, increasing medium concentrations of Ca (2.80 mM) or phosphate from 2.0 to 4.0 mM lowered EM/CM ratios in the presence of PCA, PTH, and 1,25- (OH)<inf>2</inf>D<inf>3</inf>. Calcitonin markedly inhibited 1.0 mM PCA-induced<sup>203</sup>Pb efflux (EM/CM, 0.62 ± 0.06). Calcium disodium ethylene- diaminetetra-acetic acid at a medium concentration of 0.001 mM produced an equivalent net percentage of release of<sup>203</sup>Pb as that measured for 1.0 mM PCA. Duration of calcium disodium ethyl- enediaminetetra-acetic acid activity was sustained for 72 hr compared to 48 hr for PCA. It appears, therefore, that net release of<sup>203</sup>Pb produced by PCA was enhanced by PTH, 1,25-(OH)<inf>2</inf>D<inf>3</inf>, and decreased medium levels of Ca. On the other hand, the effects of PCA were inhibited by calcitonin and increased medium concentrations of Ca or phosphate. Calcium disodium ethylene dia- minetetra-acetic acid, affected by the same hormones and ionic changes as those in PCA cultures, appears to be considerably more potent and longer acting as a chelator of Pb than PCA in this in vitro system. Speculation: In bone organ culture, a rapidly mobile subcompartment of total bone lead (Pb) has been demonstrated to be the source of Pb chelated by D-penicillamine (and CaNa2EDTA or calcium disodium ethylenediaminetetra-acetic acid). This subcompartment of bone Pb in vitro is regulated in large part by the same hormones and ions that normally control bone cell metabolism. Moreover, it is likely that the effects of D-penicillamine’s chelation on bone Pb in vitro, like parathyroid hormone 1,25-(OH)aDj, and calcitonin, produce its actions on bone cell metabolism by changes in the permeability of plasma membranes, or by modifications of ionic (calcium, phosphate, and Pb) transport and redistribution from intracellular and/or extracellular sites, particularly in the cytosol and mitochondria. Therefore, the efficacy of Pb chelation by D- penicillamine from bone explants depends, in great measure, on the complexity of coexisting factors that determine the degree of inhibition and stimulation of bone resorption, as well as on translocation of ions between intra- and extracellular stores.

Original languageEnglish (US)
Pages (from-to)330-335
Number of pages6
JournalPediatric Research
Volume14
Issue number4
StatePublished - 1980

Fingerprint

Passive Cutaneous Anaphylaxis
Penicillamine
Organ Culture Techniques
Bone and Bones
Parathyroid Hormone
Acetic Acid
Calcitonin
Calcium
Lead
Calcitriol
Hormones
Chelating Agents
Phosphates
Ions

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

D-penicillamine : Its actions on lead transport in bone organ culture. / Rosen, John F.; Markowitz, Morri E.

In: Pediatric Research, Vol. 14, No. 4, 1980, p. 330-335.

Research output: Contribution to journalArticle

@article{cedec8c6abc841458eb2349e85fdc038,
title = "D-penicillamine: Its actions on lead transport in bone organ culture",
abstract = "The purpose of this study was to develop a strictly controlled chemical system in vitro to evaluate the efficacy of lead (Pb) chelators. Moreover, these experiments were carried out to understand further the complex interactions between Pb chelating agents, calcium-regulating hormones, and bone cell metabolism. The effects of D-penicillamine (PC A) on previously incorporated203Pb transport from fetal rat bone explants were examined in bone organ culture. In several experiments,203Pb and stable bone Pb content were measured, and proportional net losses or gain were found. Experimental medium/control medium (EM/CM) ratios were used to reflect inhibition or stimulation of203Pb release because these data were expressed as the net cpm released from treated bones into the EM, defined as a change in one variable, divided by the net cpm released from control bones into the appropriate CM. EM/CM ratios increased significantly (1.96 ± 0.04 to 7.28 ± 0.08) in a dose-response relationship as PCA concentrations were raised from 1.0 to 10.0 mM. Addition of parathyroid hormone (PTH) to the medium resulted in increased EM/CM ratios for203Pb at lower PCA concentrations (EM/CM 2.79 ± 0.14 at 0.10 mM PCA; 6.71 ± 0.08 at PCA 5.0 mM), compared to PCA in the media alone. This addition of PTH effected release of 4Scalcium (45Ca) (EM/CM, 1.45 ± 0.07 to 3.62 ± 0.10) at PCA concentrations from 0.10 to 10.0 mM. 1,25- Dihydroxyvitamin D3 [l,25-(OH)2D3 in combination with PCA enhanced 203Pb release, evidenced by an EM/CM ratio of 5.69 ± 0.14 at 1.0 mM PCA compared to an EM/CM ratio of 1.96 ± 0.04 when only 1.0 mM PCA was present in the medium. A decrease in medium Ca concentration from 1.40 to 0.70 mM in the presence of 1.0 mM PCA and 20 ng/ml 1,25-dihydroxyvitamin D3 enhanced the net release of 20SPb as well. In contrast, increasing medium concentrations of Ca (2.80 mM) or phosphate from 2.0 to 4.0 mM lowered EM/CM ratios in the presence of PCA, PTH, and 1,25- (OH)2D3. Calcitonin markedly inhibited 1.0 mM PCA-induced203Pb efflux (EM/CM, 0.62 ± 0.06). Calcium disodium ethylene- diaminetetra-acetic acid at a medium concentration of 0.001 mM produced an equivalent net percentage of release of203Pb as that measured for 1.0 mM PCA. Duration of calcium disodium ethyl- enediaminetetra-acetic acid activity was sustained for 72 hr compared to 48 hr for PCA. It appears, therefore, that net release of203Pb produced by PCA was enhanced by PTH, 1,25-(OH)2D3, and decreased medium levels of Ca. On the other hand, the effects of PCA were inhibited by calcitonin and increased medium concentrations of Ca or phosphate. Calcium disodium ethylene dia- minetetra-acetic acid, affected by the same hormones and ionic changes as those in PCA cultures, appears to be considerably more potent and longer acting as a chelator of Pb than PCA in this in vitro system. Speculation: In bone organ culture, a rapidly mobile subcompartment of total bone lead (Pb) has been demonstrated to be the source of Pb chelated by D-penicillamine (and CaNa2EDTA or calcium disodium ethylenediaminetetra-acetic acid). This subcompartment of bone Pb in vitro is regulated in large part by the same hormones and ions that normally control bone cell metabolism. Moreover, it is likely that the effects of D-penicillamine’s chelation on bone Pb in vitro, like parathyroid hormone 1,25-(OH)aDj, and calcitonin, produce its actions on bone cell metabolism by changes in the permeability of plasma membranes, or by modifications of ionic (calcium, phosphate, and Pb) transport and redistribution from intracellular and/or extracellular sites, particularly in the cytosol and mitochondria. Therefore, the efficacy of Pb chelation by D- penicillamine from bone explants depends, in great measure, on the complexity of coexisting factors that determine the degree of inhibition and stimulation of bone resorption, as well as on translocation of ions between intra- and extracellular stores.",
author = "Rosen, {John F.} and Markowitz, {Morri E.}",
year = "1980",
language = "English (US)",
volume = "14",
pages = "330--335",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - D-penicillamine

T2 - Its actions on lead transport in bone organ culture

AU - Rosen, John F.

AU - Markowitz, Morri E.

PY - 1980

Y1 - 1980

N2 - The purpose of this study was to develop a strictly controlled chemical system in vitro to evaluate the efficacy of lead (Pb) chelators. Moreover, these experiments were carried out to understand further the complex interactions between Pb chelating agents, calcium-regulating hormones, and bone cell metabolism. The effects of D-penicillamine (PC A) on previously incorporated203Pb transport from fetal rat bone explants were examined in bone organ culture. In several experiments,203Pb and stable bone Pb content were measured, and proportional net losses or gain were found. Experimental medium/control medium (EM/CM) ratios were used to reflect inhibition or stimulation of203Pb release because these data were expressed as the net cpm released from treated bones into the EM, defined as a change in one variable, divided by the net cpm released from control bones into the appropriate CM. EM/CM ratios increased significantly (1.96 ± 0.04 to 7.28 ± 0.08) in a dose-response relationship as PCA concentrations were raised from 1.0 to 10.0 mM. Addition of parathyroid hormone (PTH) to the medium resulted in increased EM/CM ratios for203Pb at lower PCA concentrations (EM/CM 2.79 ± 0.14 at 0.10 mM PCA; 6.71 ± 0.08 at PCA 5.0 mM), compared to PCA in the media alone. This addition of PTH effected release of 4Scalcium (45Ca) (EM/CM, 1.45 ± 0.07 to 3.62 ± 0.10) at PCA concentrations from 0.10 to 10.0 mM. 1,25- Dihydroxyvitamin D3 [l,25-(OH)2D3 in combination with PCA enhanced 203Pb release, evidenced by an EM/CM ratio of 5.69 ± 0.14 at 1.0 mM PCA compared to an EM/CM ratio of 1.96 ± 0.04 when only 1.0 mM PCA was present in the medium. A decrease in medium Ca concentration from 1.40 to 0.70 mM in the presence of 1.0 mM PCA and 20 ng/ml 1,25-dihydroxyvitamin D3 enhanced the net release of 20SPb as well. In contrast, increasing medium concentrations of Ca (2.80 mM) or phosphate from 2.0 to 4.0 mM lowered EM/CM ratios in the presence of PCA, PTH, and 1,25- (OH)2D3. Calcitonin markedly inhibited 1.0 mM PCA-induced203Pb efflux (EM/CM, 0.62 ± 0.06). Calcium disodium ethylene- diaminetetra-acetic acid at a medium concentration of 0.001 mM produced an equivalent net percentage of release of203Pb as that measured for 1.0 mM PCA. Duration of calcium disodium ethyl- enediaminetetra-acetic acid activity was sustained for 72 hr compared to 48 hr for PCA. It appears, therefore, that net release of203Pb produced by PCA was enhanced by PTH, 1,25-(OH)2D3, and decreased medium levels of Ca. On the other hand, the effects of PCA were inhibited by calcitonin and increased medium concentrations of Ca or phosphate. Calcium disodium ethylene dia- minetetra-acetic acid, affected by the same hormones and ionic changes as those in PCA cultures, appears to be considerably more potent and longer acting as a chelator of Pb than PCA in this in vitro system. Speculation: In bone organ culture, a rapidly mobile subcompartment of total bone lead (Pb) has been demonstrated to be the source of Pb chelated by D-penicillamine (and CaNa2EDTA or calcium disodium ethylenediaminetetra-acetic acid). This subcompartment of bone Pb in vitro is regulated in large part by the same hormones and ions that normally control bone cell metabolism. Moreover, it is likely that the effects of D-penicillamine’s chelation on bone Pb in vitro, like parathyroid hormone 1,25-(OH)aDj, and calcitonin, produce its actions on bone cell metabolism by changes in the permeability of plasma membranes, or by modifications of ionic (calcium, phosphate, and Pb) transport and redistribution from intracellular and/or extracellular sites, particularly in the cytosol and mitochondria. Therefore, the efficacy of Pb chelation by D- penicillamine from bone explants depends, in great measure, on the complexity of coexisting factors that determine the degree of inhibition and stimulation of bone resorption, as well as on translocation of ions between intra- and extracellular stores.

AB - The purpose of this study was to develop a strictly controlled chemical system in vitro to evaluate the efficacy of lead (Pb) chelators. Moreover, these experiments were carried out to understand further the complex interactions between Pb chelating agents, calcium-regulating hormones, and bone cell metabolism. The effects of D-penicillamine (PC A) on previously incorporated203Pb transport from fetal rat bone explants were examined in bone organ culture. In several experiments,203Pb and stable bone Pb content were measured, and proportional net losses or gain were found. Experimental medium/control medium (EM/CM) ratios were used to reflect inhibition or stimulation of203Pb release because these data were expressed as the net cpm released from treated bones into the EM, defined as a change in one variable, divided by the net cpm released from control bones into the appropriate CM. EM/CM ratios increased significantly (1.96 ± 0.04 to 7.28 ± 0.08) in a dose-response relationship as PCA concentrations were raised from 1.0 to 10.0 mM. Addition of parathyroid hormone (PTH) to the medium resulted in increased EM/CM ratios for203Pb at lower PCA concentrations (EM/CM 2.79 ± 0.14 at 0.10 mM PCA; 6.71 ± 0.08 at PCA 5.0 mM), compared to PCA in the media alone. This addition of PTH effected release of 4Scalcium (45Ca) (EM/CM, 1.45 ± 0.07 to 3.62 ± 0.10) at PCA concentrations from 0.10 to 10.0 mM. 1,25- Dihydroxyvitamin D3 [l,25-(OH)2D3 in combination with PCA enhanced 203Pb release, evidenced by an EM/CM ratio of 5.69 ± 0.14 at 1.0 mM PCA compared to an EM/CM ratio of 1.96 ± 0.04 when only 1.0 mM PCA was present in the medium. A decrease in medium Ca concentration from 1.40 to 0.70 mM in the presence of 1.0 mM PCA and 20 ng/ml 1,25-dihydroxyvitamin D3 enhanced the net release of 20SPb as well. In contrast, increasing medium concentrations of Ca (2.80 mM) or phosphate from 2.0 to 4.0 mM lowered EM/CM ratios in the presence of PCA, PTH, and 1,25- (OH)2D3. Calcitonin markedly inhibited 1.0 mM PCA-induced203Pb efflux (EM/CM, 0.62 ± 0.06). Calcium disodium ethylene- diaminetetra-acetic acid at a medium concentration of 0.001 mM produced an equivalent net percentage of release of203Pb as that measured for 1.0 mM PCA. Duration of calcium disodium ethyl- enediaminetetra-acetic acid activity was sustained for 72 hr compared to 48 hr for PCA. It appears, therefore, that net release of203Pb produced by PCA was enhanced by PTH, 1,25-(OH)2D3, and decreased medium levels of Ca. On the other hand, the effects of PCA were inhibited by calcitonin and increased medium concentrations of Ca or phosphate. Calcium disodium ethylene dia- minetetra-acetic acid, affected by the same hormones and ionic changes as those in PCA cultures, appears to be considerably more potent and longer acting as a chelator of Pb than PCA in this in vitro system. Speculation: In bone organ culture, a rapidly mobile subcompartment of total bone lead (Pb) has been demonstrated to be the source of Pb chelated by D-penicillamine (and CaNa2EDTA or calcium disodium ethylenediaminetetra-acetic acid). This subcompartment of bone Pb in vitro is regulated in large part by the same hormones and ions that normally control bone cell metabolism. Moreover, it is likely that the effects of D-penicillamine’s chelation on bone Pb in vitro, like parathyroid hormone 1,25-(OH)aDj, and calcitonin, produce its actions on bone cell metabolism by changes in the permeability of plasma membranes, or by modifications of ionic (calcium, phosphate, and Pb) transport and redistribution from intracellular and/or extracellular sites, particularly in the cytosol and mitochondria. Therefore, the efficacy of Pb chelation by D- penicillamine from bone explants depends, in great measure, on the complexity of coexisting factors that determine the degree of inhibition and stimulation of bone resorption, as well as on translocation of ions between intra- and extracellular stores.

UR - http://www.scopus.com/inward/record.url?scp=0018837347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018837347&partnerID=8YFLogxK

M3 - Article

C2 - 6769090

AN - SCOPUS:0018837347

VL - 14

SP - 330

EP - 335

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 4

ER -